Immix Biopharma prices $100M equity raise via common stock and warrant offering

Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX]) has priced an underwritten offering [https://seekingalpha.com/pr/20331107-immix-biopharma-announces-pricing-of-upsized-100-million-underwritten-offering-of-common] structured to generate $100 million in gross proceeds, that consists of 19,117,646 shares of common stock at $5.10 per share and pre-funded warrants for 490,196 shares at $5.09 per warrant.

The company intends to use the net proceeds, alongside existing cash and its CIRM grant funds, primarily to finance the development of its drug NXC-201, as well as working capital and general corporate purposes.

Immix projects that this capital injection will be sufficient to cover its operational needs into mid-2027.

The transaction is slated to close on or about December 9, 2025.

MORE ON IMMIX BIOPHARMA, INC.

* Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' [https://seekingalpha.com/article/4839472-immix-biopharma-i-am-surprised-to-reaffirm-a-buy]
* Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. [https://seekingalpha.com/symbol/IMMX/ratings/quant-ratings]
* Historical earnings data for Immix Biopharma, Inc. [https://seekingalpha.com/symbol/IMMX/earnings]
* Financial information for Immix Biopharma, Inc. [https://seekingalpha.com/symbol/IMMX/income-statement]